Skip to main content
    U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.87
    +1.77 (+6.30%)

    Market Cap: $1.28B

    Last updated: Nov 17, 2026 at 6:00 PM ET

    UroGen Pharma Ltd (URGN) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    UroGen Pharma (URGN) has a latest price of $29.87 on Nov 17, 2026, 41.2% below its 52-week high of $50.81. Its price rose 25.7% over the past 12 months. The month-end price rose 83.3% since May 2017, a compound annual rate of 6.6%.

    Price Chart

    From May 2017 to Oct 2026, its highest month-end close was $60.12 in May 2018 and its lowest $4.24 in May 2025, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart URGN with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for URGN.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 40.6%, and over 6 months it rose 5.7%. The month-end price rose 191.9% over the 3 years through Oct 2026, a compound annual rate of 42.9%.

    PeriodChange
    1 month-12.5%
    3 months-40.6%
    6 months+5.7%
    12 months+25.7%
    12 months, with dividends+25.7%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years+191.9%+42.9%
    5 years+90.2%+13.7%
    Since May 2017+83.3%+6.6%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2025, when the price rose 119.9%, and its weakest was 2021, when it fell 47.2%.

    YearCloseChange
    2026 through Oct 2026$32.72+39.7%
    2025$23.42+119.9%
    2024$10.65-29.0%
    2023$15.00+69.1%
    2022$8.87-6.7%
    2021$9.51-47.2%
    2020$18.02-46.0%
    2019$33.37-22.5%
    2018$43.06+15.7%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 17.9% below its 50-day average of $36.40 and 6.0% below its 200-day average of $31.78.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$29.87
    52-week high$50.81-41.2%
    52-week low$16.50+81.0%
    50-day average$36.40-17.9%
    200-day average$31.78-6.0%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 79.7%.

    MeasureValue
    1-year beta1.17
    Largest fall, 1 year-50.8%
    Largest fall, 3 years-79.7%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About URGN

    What is URGN's 1-year price change?

    UroGen Pharma's price rose 25.7% over the past 12 months. With dividends included, the 12-month total return was 25.7%.

    What is URGN's 5-year price change?

    UroGen Pharma's month-end price rose 90.2% over the 5 years through Oct 2026, a compound annual rate of 13.7%. These figures leave out dividends.

    What is URGN's 52-week high and low?

    UroGen Pharma's 52-week high is $50.81 and its 52-week low is $16.50. Its latest price of $29.87 on Nov 17, 2026 is 41.2% below the high.

    What is URGN's beta?

    UroGen Pharma's 1-year beta against the S&P 500 is 1.17, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 50.8%.

    Is the URGN chart free?

    Yes. Advanced Charting for URGN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.